-
DiscoveryWomen in Science: Sandrine Piret-GérardSandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.
Discovery -
Access to HealthcareAsian health experts call for final push to wipe out deadliest form of malariaThe most lethal strain could be eliminated by 2030, but major hurdles remain.
Access to Healthcare -
Counting on combos for complex liver diseasesThe best treatment for multifaceted diseases like NASH may be combinations of drugs.
-
Bringing gene therapy into focusDr. Botond Roska says we should keep our eyes on gene therapy.
-
From Our LabsWhat goes wrong with the window to the soul in glaucoma?Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.
From Our Labs -
DiscoveryExperimental gene therapy discovered in-house enters clinical testingNovartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
Discovery -
DiscoveryVisualizing immuno-oncology researchLearn how Novartis researchers are working to outsmart tumors.
Discovery -
People and CultureEnabling 130,000 employees to grow in an organization committed to continuous learningOur Chief Learning Officer, Simon Brown, talks about our ongoing efforts to build new capabilities by investing in our own people.
People and Culture -
Access to HealthcareNovartis Access impact evaluation: progress update on our work with Boston UniversityBoston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.
Access to Healthcare -
From Our LabsHow a 19th-century technology is speeding up drug discoveryPneumatic tube systems have existed for 150+ years and have transported everything from telegrams to aircraft parts. Now they’re being used in our labs.
From Our Labs -
People and CultureFlexibility at Novartis: Deepti MittalMittal shares how flexible working helped her and her family get through a difficult time.
People and Culture -
People and CultureFlexibility at Novartis: Peter CanavanCanavan describes how flexible working positively impacts his team.
People and Culture